COPD Treatment Guidelines

Current Treatment Recommendations

The Canadian Thoracic Society strongly recommends LAMA/LABA dual therapy as initial maintenance therapy for patients with moderate COPD and low exacerbation risk, with a strong recommendation and moderate certainty of evidence 1, 2.
LAMA/LABA dual therapy has shown superior efficacy over monotherapy with a similar safety profile, and is recommended for patients with moderate to high symptoms but low exacerbation risk 1.
ICS-containing regimens carry an increased pneumonia risk that may not be justified in patients with low exacerbation risk, with a number needed to harm of 33 patients for 1 year to cause one pneumonia 1, 3.

For patients with moderate COPD and high exacerbation risk, LAMA/LABA/ICS triple therapy in a single inhaler is recommended to reduce mortality and exacerbations, with a strong recommendation and moderate certainty of evidence 2, 4.
Triple therapy has shown greater benefit in reducing mortality compared to LAMA/LABA dual therapy, with a number needed to treat of four patients for 1 year to prevent one moderate to severe exacerbation 2.

The appropriateness of the current regimen depends on the patient's exacerbation history and symptom burden, and should be reassessed based on current guidelines 1, 2.
Single-inhaler triple therapy is preferred over multiple inhalers due to potential increased benefits, improved adherence, and reduced chance of errors in inhaler technique 4.
Step-down from triple therapy to dual therapy is not recommended for patients at high risk of exacerbations, particularly those with elevated blood eosinophil counts 5, 6.

The American Thoracic Society recommends against combining Advair Diskus (ICS/LABA) and Stiolto (LAMA/LABA) due to duplication of LABA therapy, which increases the risk of adverse effects such as tremor, tachycardia, and hypokalemia 7, 8

For patients with low exacerbation risk (≤1 moderate exacerbation in the past year without hospitalization), LAMA/LABA dual therapy alone is the recommended initial maintenance therapy, as it provides significant improvement in lung function with lower rates of pneumonia 7, 8
The Canadian Thoracic Society is not referenced in this fact, however, LAMA/LABA dual therapy is preferred over ICS/LABA for patients with moderate-to-high symptom burden and impaired lung function 8
For patients with high exacerbation risk (≥2 moderate exacerbations or ≥1 severe exacerbation in the past year), LAMA/LABA/ICS triple therapy in a single inhaler is strongly recommended, with moderate certainty of evidence for reducing mortality and exacerbations 9

In patients with COPD-asthma overlap, ICS/LABA combination therapy is preferred to LAMA/LABA, but adding Stiolto on top of Advair is not justified 8
Stepping down from triple therapy is not recommended for high-risk patients, particularly those with elevated blood eosinophil counts, as withdrawing ICS may increase exacerbation risk 9
Monitoring for pneumonia risk is necessary when using ICS-containing regimens, as this is the primary adverse effect that must be balanced against exacerbation reduction benefits 9